# Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

> **NCT01857817** · PHASE2 · TERMINATED · sponsor: **Vicus Therapeutics** · enrollment: 35 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** VT-122
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01857817
- **Lead sponsor:** Vicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Low patient recruitment
- **Last updated:** 2018-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857817, "Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01857817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*